Find

Department of Clinical Medicine

Infectious Diseases

Publications

Sort by: Date | Author | Title

Larsen, C. S. (2022). Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. International Journal of Infectious Diseases, 122, 599-601. https://doi.org/10.1016/j.ijid.2022.06.059

Lau, J. S. Y., Cromer, D., Pinkevych, M., Lewin, S. R., Rasmussen, T. A., McMahon, J. H. & Davenport, M. P. (2022). Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design. The Journal of Infectious Diseases, 226(2), 236-245. https://doi.org/10.1093/infdis/jiac032

Wood, G., Kirkevang, T. S., Agergaard, J., Leth, S., Hansen, E. S. S., Laustsen, C., Larsen, A. H., Jensen, H. K., Østergaard, L. J., Bøtker, H. E., Poulsen, S. H. & Kim, W. Y. (2022). Cardiac Performance and Cardiopulmonary Fitness After Infection With SARS-CoV-2. Frontiers in Cardiovascular Medicine, 9, Article 871603. https://doi.org/10.3389/fcvm.2022.871603

Rise, N., Touborg, T., Lundsted, D. H., Dalager-Pedersen, M. & Mogensen, T. H. (2022). Case report: Evolution of pulmonary manifestations and virological markers in critical COVID-19 infection in Bruton’s agammaglobulinemia. Frontiers in Immunology, 13, Article 1057065. https://doi.org/10.3389/fimmu.2022.1057065

Lende, S. S. F., Pahus, M. H., Monrad, I., Olesen, R., Mahr, A. R., Vibholm, L. K., Østergaard, L., Søgaard, O. S., Andersen, A. H. F., Denton, P. W. & Tolstrup, M. (2022). CD169 (Siglec-1) as a Robust Human Cell Biomarker of Toll-Like Receptor 9 Agonist Immunotherapy. Frontiers in Cellular and Infection Microbiology, 12, Article 919097. https://doi.org/10.3389/fcimb.2022.919097

Hybel, T. E., Vase, M. Ø., Lauridsen, K. L., Enemark, M. B., Møller, M. B., Pedersen, C., Pedersen, G., Hamilton-Dutoit, S., Obel, N., Schade Larsen, C., d’Amore, F. & Ludvigsen, M. (2022). CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus. Leukemia & Lymphoma, 63(6), 1479-1483. https://doi.org/10.1080/10428194.2021.2023741

Berg, P., Sorensen, M. V., Rousing, A. Q., Olesen, H. V., Jensen-Fangel, S., Jeppesen, M. & Leipziger, J. (2022). Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis. Annals of Internal Medicine, 175(11), 1543-1551. https://doi.org/10.7326/M22-1741

Søgaard, O. S., Reekie, J., Johansen, I. S., Nielsen, H., Benfield, T., Wiese, L., Stærke, N. B., Iversen, K., Fogh, K., Bodilsen, J., Iversen, M., Knudsen, L. S., Klastrup, V., Larsen, F. D., Andersen, S. D., Hvidt, A. K., Andreasen, S. R., Madsen, L. W., Lindvig, S. O. ... ENFORCE Writing Group (2022). Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study. Clinical Microbiology and Infection, 28(8), 1126-1133. https://doi.org/10.1016/j.cmi.2022.03.003

Søgaard, O. S. & ENFORCE Writing Group (2022). Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: author's response. Clinical Microbiology and Infection, 28(11), 1518. https://doi.org/10.1016/j.cmi.2022.06.014

Agergaard, J., Ullahammer, W. M., Gunst, J. D., Østergaard, L. & Schiøttz-Christensen, B. (2022). Characteristics of a Danish Post-COVID Cohort Referred for Examination due to Persistent Symptoms Six Months after Mild Acute COVID-19. Journal of Clinical Medicine, 11(24), Article 7338. https://doi.org/10.3390/jcm11247338

Displaying results 531 to 540 out of 2102

54

Revised 11.09.2025

-

Lotte Bjerregaard Snabe